SPG(SH:600529) Zheng Quan Zhi Xing·2025-06-22 08:18Core Viewpoint - The announcement details the progress of a restructuring involving Shandong Pharmaceutical Glass Co., Ltd., where the controlling shareholder will change from Luzhong Investment to China National Pharmaceutical Group Corporation (Sinopharm Group) through an investment agreement [1][2][7]. Group 1: Restructuring Details - The investment cooperation agreement was signed between Sinopharm International, Sinopharm International Hong Kong, and Luzhong Investment, allowing Sinopharm to acquire a 51% stake in Luzhong Investment [1][2]. - Following the completion of this investment, Sinopharm will indirectly control 129,380,980 shares of Shandong Pharmaceutical Glass, representing approximately 19.5% of the total share capital [3][7]. - The restructuring aims to enhance the biopharmaceutical and health industry in Zibo City and Yiyuan County, aligning with national strategies for industrial modernization [2][3]. Group 2: Governance and Management - Post-investment, Luzhong Investment will remain the controlling shareholder of Shandong Pharmaceutical Glass, with Sinopharm as the indirect controlling entity [3][7]. - The current management team of Shandong Pharmaceutical Glass is expected to remain stable, with appointments made by the board in compliance with relevant laws [3][7]. - The agreement stipulates that all recommended board members and senior management must meet legal qualifications [3][4]. Group 3: Financial Implications - The investment will increase Luzhong Investment's registered capital from 300 million RMB to approximately 612.24 million RMB, with Sinopharm and its Hong Kong subsidiary contributing a total of approximately 2.45 billion RMB [6][7]. - The restructuring is not expected to adversely affect the company's ongoing operations or financial status, maintaining its independence [2][7].